You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

T-cell attacking cancer tumour

Oncology

At GSK we are committed to improving outcomes for patients who are affected by cancer. Browse our therapeutic area sites below.

Haematology

Gynaecological cancer

POM. Further information is available from GlaxoSmithKline (Ireland) Ltd

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-ON-WCNT-260001 | January 2026